WALTHAM, Mass., May 29, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a late-stage oncology company, announced today that updated

A vaccine that targets cancer cells in combination with the drug letrozole, a standard hormonal therapy against breast cancer, significantly increased survival when tested in mice.

Preoperative treatment with aromatase inhibitors increases the likelihood that postmenopausal women with estrogen receptor-positive breast cancer will be able to have breast-conserving surgery rather than a mastectomy.

Two studies published March 6 in the Journal of the National Cancer Institute provide insights about the CYP2D6 genotype in postmenopausal breast cancer patients and represent a major step forward in understanding the usefulness of CYP2D6 testing for deciding whether or not a patient should receive adjuvant tamoxifen for treatment of early-stage breast cancer.

Big Mountain Drugs, a licensed Canadian online pharmacy, is responding to the recent medication shortage by offering $25.00 off any cancer therapy order over $100.00.